{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Instil Bio, Inc."},"Symbol":{"label":"Symbol","value":"TIL"},"Address":{"label":"Address","value":"3963 MAPLE AVENUE,SUITE 350, DALLAS, Texas, 75219, United States"},"Phone":{"label":"Phone","value":"+1 972 499-3350"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma."},"CompanyUrl":{"label":"Company Url","value":"https://www.instilbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bronson Crouch","title":"Chairman & Chief Executive Officer"},{"name":"Mark Dudley","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}